| 中文名称 | 马西替坦 |
|---|---|
| 中文别名 | 马西替坦;N-[5-(4-溴苯基)-6-[2-[(5-溴-2-嘧啶基)氧]乙氧基]-4-嘧啶基]-N'-丙基磺酰胺;Macitentan 抑制剂;马西替坦 Macitentan;马西替坦标准品;马西替坦杂质;美西特田;美西特田-D7;美西特田标准品 |
| 英文名称 | Macitentan |
| 英文别名 | Macitentan;N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide;5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-N-(propylsulfamoyl)pyrimidin-4-amine;ACT064992;N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)-oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide;Boceprevir-d9;ACT-064992;Actelion-1;Opsumit;C02KX04;N-(5-(4-Bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)-N'-propylsulfamide;N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'- propylsulfamide;CHEBI:76607;AS-74590;DTXCID60118554;MACITENTAN [USAN];s8051;SW219473-1;NCGC00346456-01;Sulfamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propyl-; N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide; ACT 064992; Macitentan; Opsumit; Propylsulfamic acid N-[5-(4-bromophenyl)-6-[2-[(5-bromopyrimidin-2-yl)oxy]ethoxy]pyrimidin-4-yl]amide;D10135;ACT 064992; ACT-064992;CHEMBL2103873;HMS3653N06;Sulfamide, N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propyl-;UNII-Z9K9Y9WMVL;macitentanum;MACITENTAN [WHO-DD];MACITENTAN [VANDF];SCHEMBL1445625;JGCMEBMXRHSZKX-UHFFFAOYSA-N;BCP05309;Opsumit (TN);n-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-n'-propylaminosulfonamide;MACITENTAN [ORANGE BOOK];SMR004702943;FT-0696675;CCG-270155;AM81244;Macitentan- Bio-X;HMS3747E09;cas:441798-33-0;Macitentan;MFCD17167076;NS00072551;EN300-7404089;Z9K9Y9WMVL;AC-30102;N-(5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXI)ETHOXY)PYRIMIDIN-4-YL)-N'-PROPYLSULFURIC DIAMIDE;MLS006011174;NCGC00346456-05;Q6724151;EX-A544;DTXSID50196063;N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'-propylsulfuric diamide;Macitentan (Actelion-1,ACT-064992);SULFAMIDE, N-(5-(4-BROMOPHENYL)-6-(2-((5-BROMO-2-PYRIMIDINYL)OXY)ETHOXY)-4-PYRIMIDINYL)-N'-PROPYL-;DB08932;441798-33-0;N-(5-(4-Bromophenyl)-6-(2-((5-bromo-2-pyrimidinyl)oxy)ethoxy)-4-pyrimidinyl)-N'-propylsulfamide;CS-0686;MACITENTAN [MI];MACITENTAN [JAN];Macitentan [USAN:INN];BDBM50395626;{[5-(4-BROMOPHENYL)-6-{2-[(5-BROMOPYRIMIDIN-2-YL)OXY]ETHOXY}PYRIMIDIN-4-YL]SULFAMOYL}(PROPYL)AMINE;BM162771;Macitentan [INN];HY-14184;SB14841;AKOS024463406;Macitentan (JAN/USAN);N-(5-(4-Bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)-N'-propylsulfuric diamide;GTPL7352;ACT 064992;BRD-K48812570-001-02-3;OPSYNVI COMPONENT MACITENTAN;Macitentan (Actelion-1,ACT-064992)?;A1D5I;DB-070519;Opsynvi (combination of macitentan + tadalafil);BRD-K48812570-001-03-1 |
| CAS No. | 441798-33-0 |
| 分子式 | C19H20Br2N6O4S |
| 分子量 | 588.27 |
4-(2-((2R,3R)-3-(2,5-二氟苯基)-3-羟基-4-(1H-1,2,4-三唑-1-基)丁-2-基)噻唑-4-基)苯甲腈
N-(丁基磺酰基)-O-[4-(4-哌啶基)丁基]-L-酪氨酸盐酸盐一水合物
2-(4-(1-羟基-4-(4-(羟基二苯基甲基)哌啶-1-基)丁基)苯基)-2-甲基丙酸
7-环戊基-N,N-二甲基-2-((5-(哌嗪-1-基)吡啶-2-基)氨基)-7H-吡咯并[2,3-d]嘧啶-6-甲酰胺
(1-((2R,3R,4S,5R)-3,4-二羟基-5-甲基四氢呋喃-2-基)-5-氟-2-氧代-1,2-二氢嘧啶-4-基)氨基甲酸戊酯
((3S,5R)-5-((1H-1,2,4-三唑-1-基)甲基)-5-(2,4-二氟苯基)四氢呋喃-3-基)甲基 4-甲基苯磺酸酯
N-(3-氯-4-氟苯基)-7-甲氧基-6-(3-吗啉-4-丙氧基)喹唑啉-4-胺
(6R,7R)-3-甲基-7-[(R)-2-氨基-2-苯乙酰氨基]-8-氧-5-硫杂-1-双环[4.2.0]辛-2-烯-2-甲酸
(2R,3S,5S)-3-苄氧基-5-[2-[[(4-甲氧基苯基)二苯基甲基]氨基]-6-苄氧基-9H-嘌呤-9-基]-2-苄氧基甲基环戊醇
(2R,3R,4S,5R)-2-(4-氨基吡咯并[2,1-F][1,2,4]三嗪-7-基)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-甲腈
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。
CopyRight @2025 广东元丰化学试剂有限公司 版权所有 | 隐私政策 条款及条件 | 粤ICP备2025403430号-1
技术支持:库价化学